MPM Capital CEO and leadership

Detlev Biniszkiewicz, Ph.D., joined MPM in 2018 as a Managing Director and is responsible for the identification and evaluation of new investment opportunities as well as providing operational and strategic guidance to the firm’s portfolio investments. Detlev is an experienced biopharma executive and brings deep knowledge of oncology and immuno-oncology to this role. Most recently, Detlev was the President and CEO of Surface Oncology (SURF), where he led its growth and transformation through to clinical-stage and its preparation for a public offering. Prior to Surface Oncology, he was Vice President of Strategy in AstraZeneca’s Oncology Unit and was part of the oncology leadership that developed Lynparza® and Tagrisso® – two innovative medicines that help thousands of patients suffering from cancer. His group transformed AstraZeneca’s Oncology pipeline through numerous licensing deals, clinical alliances, and academic collaborations. Detlev has also held multiple roles at Novartis including Global Head of Portfolio Management and Analysis, where his group provided oversight of Novartis’ research and early development portfolio. Detlev began his career as a Principal at the Boston Consulting Group (BCG) and performed his academic research with Dr. Rudolf Jaenisch at the Whitehead Institute at the Massachusetts Institute of Technology in Cambridge, MA.

Kristen Laguerre is a Steering Committee Member at Women in Alternative Assets Inc, Partner/CFO at Flare Capital Partners, and Executive Partner at MPM Capital and is based in Boston, Massachusetts. She has worked as Experienced Manager at Arthur Andersen LLP; Vice President, Finance at Soft Bank Capital; and Board Member at Private Equity Chief Financial Officer Association (PECFOA). Kristen works or has worked as BOARD MEMBER at Private Equity CFO Assn and MEMBER at CFO Task Force of the National Venture Capital Assn. She attended Boston University and Wesleyan University.